Insmed Incorporated (LON:0JAV)
184.05
-2.19 (-1.18%)
At close: Nov 7, 2025
Insmed Revenue
Insmed had revenue of $142.34M USD in the quarter ending September 30, 2025, with 52.36% growth. This brings the company's revenue in the last twelve months to $447.02M, up 30.34% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$447.02M
Revenue Growth
+30.34%
P/S Ratio
92.40
Revenue / Employee
$351.71K
Employees
1,271
Market Cap
30.73B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Insmed News
- 2 days ago - Artisan Global Opportunities Fund Q3 2025 Portfolio Update - Seeking Alpha
- 3 days ago - American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors - Seeking Alpha
- 4 days ago - Insmed To Present at November and December 2025 Investor Conferences - PRNewsWire
- 5 days ago - Latest read on rare disease gene therapy from Insmed CEO Will Lewis - CNBC
- 8 days ago - Wells Fargo Raises Price Target for INSM to $217, Maintains Overweight Rating | INSM Stock News - GuruFocus
- 8 days ago - Goldman Sachs Boosts Insmed (INSM) Price Target to $225 | INSM Stock News - GuruFocus
- 8 days ago - INSM: UBS Maintains 'Buy', Raises Price Target to $223 | INSM Stock News - GuruFocus
- 8 days ago - Insmed (INSM) Sees Price Target Raised by RBC Capital to $215 | INSM Stock News - GuruFocus